好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

DTI Evidence of Microstructural Damage to the Striatum in Subjects with Multiple Sclerosis
MS and Related Diseases
P06 - (-)
107
BACKGROUND: GM damage is an established, clinically relevant feature of MS. DTI is a sensitive tool to disclose deep GM degeneration, as fractional anisotropy (FA) of the caudate and thalamus has been shown to be increased in subjects with MS. Clinical relevance of such changes has been argued following observed correlations with disease duration, disability scores and cerebral white matter (WM) lesion burden in T2-weighted images. Here we report on DTI changes in the deep GM in MS patients, including the putamen, a structure of interest that has not yet been investigated with DTI in MS. We also addressed the impact of these changes on motor performance.
DESIGN/METHODS: We compared DTI-derived FA and mean diffusivity of the caudate, putamen and thalamus between 30 MS patients (25 relapsing-remitting and 5 secondary progressive) and 10 controls. Correlation analyses between DTI metrics of the structures of interest and clinical data, including disability (EDSS) and mobility indexes (ambulation index and 25-ft walk time), were investigated in the subjects with MS.
RESULTS: FA of both the caudate (p=0.007) and the putamen (p=0.04) was higher in MS patients compared to controls. Caudate FA was positively correlated with EDSS (r=0.42, p=0.02) and ambulation index (r=0.38, p=0.04) in MS patients, controlling for age and gender. Putamen FA, but not caudate FA, correlated with FLAIR white matter lesion burden (r=0.40, p=0.03) in the patients. No other associations between DTI metrics of the structures of interest and clinical parameters were found.
CONCLUSIONS: Increased FA in the striatum may represent a marker of microstructural damage to the deep GM in subjects with MS.
Authors/Disclosures
Michele Cavallari, MD (Brigham and Woman's Hospital)
PRESENTER 		The institution of Dr. Cavallari has received research support from BrightFocus Foundation. The institution of Dr. Cavallari has received research support from Brigham Research Institute. The institution of Dr. Cavallari has received research support from Department of Radiology at Brigham and Women's Hospital. The institution of Dr. Cavallari has received research support from Hebrew SeniorLife Rehabilitation Center. Dr. Cavallari has received intellectual property interests from a discovery or technology relating to health care.
Antonia Ceccarelli, MD, PhD (Epicura Centre Hospitalier, VUB) No disclosure on file
Todd Grinnell, PhD Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
No disclosure on file
Mohit Neema, MD No disclosure on file
Rohit Bakshi, MD, FAAN Dr. Bakshi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Bakshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. The institution of Dr. Bakshi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Neuroimaging. The institution of Dr. Bakshi has received research support from Bristol Myers Squibb. The institution of Dr. Bakshi has received research support from EMD Serono. The institution of Dr. Bakshi has received research support from Novartis.
Charles R. Guttmann Charles R.G. Guttmann has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sintetica SA. Charles R.G. Guttmann has received stock or an ownership interest from Alnylam. Charles R.G. Guttmann has received stock or an ownership interest from Roche. Charles R.G. Guttmann has received stock or an ownership interest from Novartis. Charles R.G. Guttmann has received stock or an ownership interest from Arrowhead Pharmaceuticals. Charles R.G. Guttmann has received stock or an ownership interest from Protalix. Charles R.G. Guttmann has received stock or an ownership interest from Promethee. Charles R.G. Guttmann has received stock or an ownership interest from GSK. Charles R.G. Guttmann has received stock or an ownership interest from Sangamo. Charles R.G. Guttmann has received stock or an ownership interest from Alcon. Charles R.G. Guttmann has received stock or an ownership interest from Cocrystal Pharma. The institution of Charles R.G. Guttmann has received research support from NIH. The institution of Charles R.G. Guttmann has received research support from McGill University. The institution of Charles R.G. Guttmann has received research support from National Multiple Sclerosis Society. The institution of Charles R.G. Guttmann has received research support from BrightFocus Foundation. The institution of Charles R.G. Guttmann has received research support from National Multiple Sclerosis Society. The institution of Charles R.G. Guttmann has received research support from University of Connecticut Health Center. The institution of Charles R.G. Guttmann has received research support from U.S. Office of Naval Research.